2025-12368Proposed RuleSignificantWallet

Medicare Reworks the Payment Plumbing for Kidney Dialysis

Published Date: 7/2/2025

Proposed Rule

Summary

Starting in 2026, Medicare is updating how it pays for kidney dialysis for people with end-stage renal disease and those with acute kidney injury. The rule also tweaks quality programs and changes the ESRD Treatment Choices Model to improve care and payment fairness. Patients, dialysis centers, and healthcare providers should watch for these changes, with public comments open until August 29, 2025.

Analyzed Economic Effects

8 provisions identified: 1 benefits, 3 costs, 4 mixed.

CY 2026 ESRD base rate rises to $281.06

For calendar year (CY) 2026, CMS proposes an ESRD Prospective Payment System (PPS) base rate of $281.06 per treatment, up from $273.82 in CY 2025. CMS estimates aggregate Medicare payments to ESRD facilities would increase by about $160 million in CY 2026 and beneficiary coinsurance payments would increase by about 1.9% (approximately $30 million).

Continuation of TDAPA drug payments in 2026

CMS proposes post‑TDAPA add-on payment amounts for specific drugs in CY 2026: Korsuva at $0.2633 per treatment and DefenCath at $1.4780 per treatment in the quarters specified. CMS estimates combined TDAPA payments for continuing drugs in CY 2026 would be about $480 million, with roughly $100 million attributable to beneficiary coinsurance.

ESRD QIP measure removals and survey reduction

CMS proposes to remove three reporting measures from the ESRD Quality Incentive Program (QIP) beginning with Payment Year (PY) 2027: Facility Commitment to Health Equity, Screening for Social Drivers of Health, and Screen Positive Rate for Social Drivers of Health. Beginning with PY 2028, CMS proposes to update the In‑Center Hemodialysis CAHPS clinical measure and shorten the ICH CAHPS survey by removing 23 questions; CMS estimates the overall economic impact of PY 2027 at approximately $146.8 million and PY 2028 at approximately $143.1 million (including $124.7 million in information collection costs and payment reductions of about $22.1 million for PY 2027 and $18.4 million for PY 2028).

TDAPA eligibility timeframe shortened to 3 years

CMS proposes to change the TDAPA eligibility window so that a new renal dialysis drug or biological product must have been approved by the FDA within the past 3 years at the time of TDAPA application. This eligibility timeframe would apply to TDAPA applications submitted on or after January 1, 2028.

AKI dialysis payment set to $281.06

CMS proposes the annual payment rate for renal dialysis furnished to individuals with acute kidney injury (AKI) for CY 2026 to be $281.06, the same as the proposed ESRD PPS base rate. CMS estimates aggregate Medicare payments for AKI dialysis would increase by $1 million (a 1.8% increase) in CY 2026 compared to CY 2025.

Outlier payment amounts for CY 2026 decrease

CMS proposes updates to the ESRD outlier policy and would reduce the fixed dollar loss (FDL) and Medicare allowable payment (MAP) amounts for CY 2026: pediatric FDL from $234.26 to $148.38 and pediatric MAP from $59.60 to $44.09; adult FDL from $45.41 to $12.74 and adult MAP from $31.02 to $22.07. CMS reports outlier payments represented approximately 0.8% of total Medicare payments in CY 2024 (below the 1.0% target).

New payment adjustment for non‑contiguous areas (NAPA)

CMS proposes a Non-Contiguous Areas Payment Adjustment (NAPA) for ESRD facilities located in Alaska, Hawaii, Guam, American Samoa, and the Northern Mariana Islands to account for certain non-labor costs not captured in the wage index. CMS proposes the NAPA to be budget neutral and would apply a corresponding budget neutrality factor of 0.99859 to the CY 2026 ESRD PPS base rate.

ETC Model termination as of Dec 31, 2025

CMS proposes to terminate the End-Stage Renal Disease Treatment Choices (ETC) Model effective December 31, 2025, and to limit application of the 42 CFR part 512, subpart C payment adjustments to claims with service dates on or after January 1, 2021 and on or before December 31, 2025. CMS estimates the net Federal impact of terminating the ETC Model would be approximately $1 million in savings.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Effective Date
7/2/2025
1/1/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Centers for Medicare & Medicaid Services
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register